Clinical Trial

Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial

Study acronym: ALLY II TNK
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The study objective is to evaluate the safety and efficacy of Intra arterial (IA) Tenecteplase (TNK) as an adjunctive therapy in acute ischemic stroke (AIS) patients with large vessel occlusions (LVO) in the anterior circulation of Internal Carotid Artery (ICA), Middle Cerebral Arteries (M1 and M2) who achieve a reperfusion grade of Modified Treatment in Cerebral Ischemia Scale (mTICI) 2b or higher post-mechanical thrombectomy using Food and Drug Administration (FDA) approved devices.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-21; most recent amendment 2026-01-20.
Status change: Not Yet Recruiting → Recruiting 2025-05-06
Trial Details
NCT Number NCT06949228
Lead Sponsor ProMedica Health System
Conditions Ischemic Stroke, Acute Disease
Enrollment 132 participants
Start Date 2025-07-30
Primary Completion 2028-05-30 (estimated)
Study Completion 2028-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-21